Amphastar Pharmaceuticals (AMPH) Research & Development (2013 - 2026)

Amphastar Pharmaceuticals' Research & Development history runs 14 years deep, the most recent figure standing at $26.7 million for Q1 2026.

• On a quarterly basis, Research & Development rose 125.32% year-over-year to $26.7 million in Q1 2026; TTM through Mar 2026 was $68.6 million, a 30.97% increase from a year earlier, with the FY2025 full-year figure at $43.9 million, up 16.09% from the prior year.
• Research & Development grew to $26.7 million in Q1 2026 per AMPH's latest filing, from $10.3 million in the prior quarter.
• Across five years, Research & Development topped out at $26.7 million in Q1 2026 and bottomed at $4.8 million in Q3 2022.
• The 5-year median for Research & Development is $11.9 million (2025), against an average of $13.7 million.
• Across the five-year window, Research & Development plunged 63.73% in 2022 and jumped 259.03% in 2023, its largest moves.
• Year by year, Research & Development stood at $17.2 million in 2022, then plunged by 49.99% to $8.6 million in 2023, then grew by 20.94% to $10.4 million in 2024, then declined by 1.39% to $10.3 million in 2025, then surged by 160.11% to $26.7 million in 2026.
• Per Business Quant, the three latest AMPH Research & Development figures stand at $26.7 million (Q1 2026), $10.3 million (Q4 2025), and $11.5 million (Q3 2025).